Oncolytics Biotech Inc.
ONCY
$0.5919
$0.02193.84%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 2.78M | 2.28M | 2.46M | 2.21M | 3.08M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 6.03M | 7.26M | 5.79M | 6.47M | 6.50M |
Operating Income | -6.03M | -7.26M | -5.79M | -6.47M | -6.50M |
Income Before Tax | -5.71M | -6.99M | -5.23M | -5.11M | -2.87M |
Income Tax Expenses | 16.40K | 8.80K | 69.40K | -- | 31.60K |
Earnings from Continuing Operations | -5.73M | -7.00M | -5.30M | -5.11M | -2.90M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -5.73M | -7.00M | -5.30M | -5.11M | -2.90M |
EBIT | -6.03M | -7.26M | -5.79M | -6.47M | -6.50M |
EBITDA | -6.02M | -7.23M | -5.77M | -6.45M | -6.49M |
EPS Basic | -0.07 | -0.09 | -0.07 | -0.07 | -0.04 |
Normalized Basic EPS | -0.05 | -0.06 | -0.04 | -0.04 | -0.02 |
EPS Diluted | -0.07 | -0.09 | -0.07 | -0.07 | -0.04 |
Normalized Diluted EPS | -0.05 | -0.06 | -0.04 | -0.04 | -0.02 |
Average Basic Shares Outstanding | 77.57M | 77.02M | 76.09M | 75.24M | 73.80M |
Average Diluted Shares Outstanding | 77.57M | 77.02M | 76.09M | 75.24M | 73.80M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |